Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History VOR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics VOR

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Vor Biopharma Inc

VOR
Current price
2.54 USD +0.03 USD (+1.20%)
Last closed 2.67 USD
ISIN US9290331084
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 238 673 600 USD
Yield for 12 month +169.07 %
1Y
3Y
5Y
10Y
15Y
VOR
21.11.2021 - 28.11.2021

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Address: 100 Cambridgepark Drive, Cambridge, MA, United States, 02140

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1.18 USD

P/E Ratio

Dividend Yield

Financials VOR

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures VOR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

-3 492 000 USD

Current Quarter

Last Quarter

EBITDA -118 740 000 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -55.25 %
PEG Ratio
Return On Equity TTM -125.43 %
Wall Street Target Price 1.18 USD
Revenue TTM
Book Value 0.53 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -1.51 USD
Diluted Eps TTM -1.51 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation VOR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -3.09
Price Book MRQ 3.61

Technical Indicators VOR

For 52 Weeks

0.13 USD 2.04 USD
50 Day MA 0.45 USD
Shares Short Prior Month 4 194 734
200 Day MA 0.83 USD
Short Ratio 0.79
Shares Short 3 217 909
Short Percent 7.07 %